Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

2012/06/21 by Yeonmi Lee, Y.-S. Lee, M.-S. Park +13 · 32 citations
Medicine · #Diabetes Treatment and Management #Adipokines, Inflammation, and Metabolic Diseases #Pancreatic function and diabetes

paper · pdf · doi:10.1007/s00125-012-2592-3

Cited by

• Repurposing metabolic drugs as anti-inflammatory agents
• Effect of glucagon-like peptide-1 receptor agonists on circulating levels of leptin and resistin: A meta-analysis of randomized controlled trials
• GLP-1 Receptor Agonists as Emerging Modulators of Inflammation and Angiogenesis in Chronic Cutaneous Wound Healing
• Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
• Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment
• Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
• The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
• Chronic exposure to air pollution particles increases the risk of obesity and metabolic syndrome: findings from a natural experiment in Beijing. [europepmc]
• Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. [europepmc]
• Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. [europepmc]
• Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. [europepmc]
• Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. [europepmc]
• Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats. [europepmc]
• GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. [europepmc]
• Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes. [europepmc]
• Impact of Gut Microbiota on Host Glycemic Control. [europepmc]
• Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output. [europepmc]
• Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. [europepmc]
• Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. [europepmc]
• Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. [europepmc]
• Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. [europepmc]
• Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. [europepmc]
• Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. [europepmc]
• The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. [europepmc]
• Inflammatory Mechanisms of Diabetes and Its Vascular Complications. [europepmc]
• Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. [europepmc]
• GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk. [europepmc]
• Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. [europepmc]
• GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. [europepmc]
• Metaflammation in obesity and its therapeutic targeting. [europepmc]
• Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. [europepmc]
• The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. [europepmc]